Glycomacromolecules show significant potential as antimicrobials. We highlight recent studies on their performance in hindering host cell entry and biofilm formation, and their potential as drug delivery and diagnostic agents.
Heparin (HP) and heparan sulfate (HS) are linear, anionically charged polysaccharides well-known for their diverse biological activities. While HP is generally localized in mast cells and in connective tissues, HS is part of the glycocalyx and involved in the attachment of viruses to host cells, constituting the first step of an infection. HP and HS also exhibit antiviral activity by blocking viral receptors, thereby inhibiting viruses from engaging with host cells. Inspired by their structural features, such as their high molecular weight and polyanionic character, various synthetic polymers mimicking HP/HS have been developed and used as model systems to study bioactivity, as well as for therapeutic applications. This Perspective provides an overview of the roles of HP/HS in viral engagement, and examines historical and recent approaches toward oligo-/polysaccharide, glycopolymer, and anionic polymer HP/HS mimetics. An overview of current applications and future prospects of these molecules is provided, demonstrating their potential in addressing current and future epidemics and pandemics.
Sulfated glycosaminoglycans (sGAGs) make up a class of cell-surface glycans known to mediate pathogen engagement. Glycopolymers mimicking sGAGs can reduce or prevent pathogen attachment. However, their high anticoagulant activity limits their biomedical applications. Here, we report the synthesis and evaluation of synthetic glycopolymers mimicking sGAGs with high antiviral activity but low anticoagulant activity. The key lies in the control of the density of carbohydrates presented along the polymeric backbone. This was accomplished via copolymerization of carbohydrate with noncarbohydrate monomers. We reveal that the polymer chain length affects inhibition of SARS-CoV-2 pseudovirus (PsV) and authentic virus infections, and that above a critical chain length, density of carbohydrate and sulfate groups can be reduced, maintaining high antiviral activity while minimizing anticoagulant activity. This demonstrates, for the first time, how specific structural parameters of glycopolymers can be used to maximize inhibition while minimizing anticoagulative properties unlocking the full potential of sGAG mimetics in fighting infections.